UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

Journal of hepatology, 2019-05, Vol.70 (5), p.1019-1023

2019

Volltextzugriff (PDF)

Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection

World journal of gastroenterology : WJG, 2014-08, Vol.20 (31), p.10984-10993

2014

Volltextzugriff (PDF)

Chronic hepatitis C： Treat or wait？ Medical decision making in clinical practice

World journal of gastroenterology : WJG, 2012-03, Vol.18 (12), p.1339-1347

Claus Niederau Dietrich Huppe EImar Zehnter Bernd Moiler, Renate Heyne Stefan Christensen Rainer Waft Arno Theilmeier Ulrich Alshuth Stefan Mauss

2012

Volltextzugriff (PDF)

Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir

Hepatology (Baltimore, Md.), 2014-01, Vol.59 (1), p.46-48

2014

Volltextzugriff (PDF)

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

Journal of hepatology, 2017-11, Vol.67 (5), p.918-924

2017

Volltextzugriff (PDF)

Prescription of new HCV-drugs - what has to be considered judicially

Zeitschrift fur Gastroenterologie, 2015-01, Vol.53 (1), p.43

Mauss, Stefan

2015

Volltextzugriff (PDF)

Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection

Hepatology (Baltimore, Md.), 2004-12, Vol.40 (6), p.1421-1425

2004

Volltextzugriff (PDF)

Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R)

Zeitschrift fur Gastroenterologie, 2023-05, Vol.61 (5), p.489

2023

Volltextzugriff (PDF)

Reply to: “Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030”

Journal of hepatology, 2017-08, Vol.67 (2), p.420-422

2017

Volltextzugriff (PDF)

Treatment of viral hepatitis in HIV–coinfected patients–adverse events and their management

Journal of hepatology, 2006, Vol.44 (1 Suppl), p.S114-S118

Mauss, Stefan

2006

Volltextzugriff (PDF)

Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study

Clinical gastroenterology and hepatology, 2023-03, Vol.21 (3), p.713-722.e3

2023

Volltextzugriff (PDF)

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials

Liver international, 2017-02, Vol.37 (2), p.205-211

2017

Volltextzugriff (PDF)

Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry

Journal of viral hepatitis, 2021-11, Vol.28 (11), p.1660-1664

2021

Volltextzugriff (PDF)

A prospective controlled study of interferon‐based therapy of chronic hepatitis C in patients on methadone maintenance

Hepatology (Baltimore, Md.), 2004-07, Vol.40 (1), p.120-124

2004

Volltextzugriff (PDF)

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany

Digestive diseases and sciences, 2016-10, Vol.61 (10), p.3061-3071

2016

Volltextzugriff (PDF)

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial

Hepatology (Baltimore, Md.), 2013-06, Vol.57 (6), p.2155-2163

2013

Volltextzugriff (PDF)

Current recommendations for the treatment of chronic hepatitis C

Zeitschrift fur Gastroenterologie, 2014-10, Vol.52 (10), p.1185

2014

Volltextzugriff (PDF)

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

Liver international, 2018-11, Vol.38 (11), p.1906-1910

2018

Volltextzugriff (PDF)

4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)

Zeitschrift fur Gastroenterologie, 2019-01, Vol.57 (1), p.27

2019

Volltextzugriff (PDF)

Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C

Zeitschrift fur Gastroenterologie, 2019-02, Vol.57 (2), p.139

2019

Volltextzugriff (PDF)

Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries

Zeitschrift fur Gastroenterologie, 2021-03, Vol.59 (3), p.241

2021

Volltextzugriff (PDF)

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

Zeitschrift fur Gastroenterologie, 2019-05, Vol.57 (5), p.584

2019

Volltextzugriff (PDF)

Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine

Hepatology (Baltimore, Md.), 2004-02, Vol.39 (2), p.311-317

2004

Volltextzugriff (PDF)

Phylogenetic analysis of acute hepatitis C virus genotype 4 infections among human immunodeficiency virus-positive men who have sex with men in Germany

Liver international, 2010-09, Vol.30 (8), p.1169-1172

2010

Volltextzugriff (PDF)

Estimating the likelihood of sustained virological response in chronic hepatitis C therapy

Journal of viral hepatitis, 2011-04, Vol.18 (4), p.e81-e90

2011

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

KollektionTaylor & Francis:Master (3349 titles)

KollektionMEDLINE

ThemaGastroenterology & Hepatology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(28)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(28)
Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Male
(20)
Female
(19)
Middle Aged
(17)
Antiviral Agents - Therapeutic Use
(16)
Adult
(15)
Hepatitis C, Chronic - Drug Therapy
(13)
Drug Therapy, Combination
(10)
Germany
(10)
Hepatitis C
(10)
Treatment Outcome
(10)
Hepacivirus - Genetics
(8)
Hepatitis
(8)
Hepatitis C - Drug Therapy
(8)
Prospective Studies
(8)
Registries
(7)
Antiviral Agents - Administration & Dosage
(6)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection

Chronic hepatitis C： Treat or wait？ Medical decision making in clinical practice

Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

Prescription of new HCV-drugs - what has to be considered judicially

Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection

Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R)

Reply to: “Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030”

Treatment of viral hepatitis in HIV–coinfected patients–adverse events and their management

Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials

Late presentation of chronic hepatitis C patients in the era of direct‐acting antivirals—Data from the German Hepatitis C‐Registry

A prospective controlled study of interferon‐based therapy of chronic hepatitis C in patients on methadone maintenance

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial

Current recommendations for the treatment of chronic hepatitis C

Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients

4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)

Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C

Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine

Phylogenetic analysis of acute hepatitis C virus genotype 4 infections among human immunodeficiency virus-positive men who have sex with men in Germany

Estimating the likelihood of sustained virological response in chronic hepatitis C therapy

Aktive Filter

Suchergebnisse filtern